Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

Surgery doesn’t improve survival in patients with isolated severe tricuspid regurgitation, researchers have found.

The director of Duke University’s heart transplant program is promoting warm perfusion—a technique that preserves organs more effectively than a traditional cooling box—as a means of expanding the CV donor pool in the U.S.

The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.

A systematic review analyzing the cardiovascular impact of nearly two dozen armed conflicts has identified a link between war and an increased incidence of coronary heart disease, cerebrovascular and endocrine diseases, and other risk factors among civilians.

A federal review of UNC Hospital’s pediatric cardiology unit found “no current deficiencies” in the program just two months after the New York Times published an article suggesting the unit was in “total disarray."